Joining the dealmaking spree to kick off the 2025 J.P. Morgan Healthcare Conference, Eli Lilly and Co. announced it was picking up an early clinical-stage PI3Kα inhibitor program from Scorpion Therapeutics Inc. in a deal that could be worth up to $2.5 billion, while GSK plc is adding to its cancer pipeline with the acquisition of Idrx Inc. for $1 billion up front.
Scorpion Therapeutics Inc. has found compounds acting as cellular tumor antigen p53 (TP53) (Y220C mutant) activators reported to be useful for the treatment of cancer.
Phosphatidylinositol 3-kinase α (PI3Kα) (H1047R mutant) inhibitors potentially useful for the treatment of cancer have been described in a recent Scorpion Therapeutics Inc. patent.
Scorpion Therapeutics Inc. has disclosed tetrahydroindole derivatives acting as EGFR (HER1; erbB1) and/or HER2 (erbB2) inhibitors reported to be useful for the treatment of cancer.
Scorpion Therapeutics Inc. has named STX-241 as its next development candidate. STX-241 is an orally bioavailable, highly selective, central nervous system (CNS)-penetrant, fourth-generation EGFR tyrosine kinase inhibitor (TKI) designed to inhibit C797S mutations with a co-occurring EGFR exon 19 deletion or exon 21 mutation (double mutant) in non-small-cell lung cancer (NSCLC).
Scorpion Therapeutics Inc. has out-licensed two of its small-molecule EGFR inhibitors to Pierre Fabre SA in exchange for a $65 million up-front fee and could also earn up to $553 million in potential milestone payments, plus royalties on net sales.
Scorpion Therapeutics Inc. has disclosed urea derivatives acting as phosphatidylinositol 3-kinase α (PI3Kα) (H1047R mutant) inhibitors reported to be useful for the treatment of cancer.
Researchers from Scorpion Therapeutics Inc. presented the discovery and preclinical evaluation of a novel mutant-selective, allosteric phosphoinositide 3-kinase α (PI3Kα) inhibitor, STX-478. In vitro, STX-478 showed mutant selectivity, as it selectively inhibited the viability of cell lines with mutations in the PIK3CA kinase domain and helical domain.
Researchers from Scorpion Therapeutics Inc. presented preclinical data for the novel EGFR exon 20 mutant inhibitor STX-721, being developed for the treatment of non-small-cell lung cancer (NSCLC).
There are 40 years of history behind the development of phosphoinositide 3-kinase (PI3K) inhibitors, Rebecca Dent told her audience at ESMO Breast Cancer 2022. And there have been success stories. There are five FDA-approved PI3K inhibitors in several cancer types, and in April, the FDA approved Vijoice (alpelisib; Novartis AG) for PIK3CA-related overgrowth spectrum, a rare disorder resulting from germline mutations of PIK3CA.
